UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): December 18, 2017
CEL-SCI CORPORATION
-------------------------------------
(Exact name of Registrant as specified in its charter)
Colorado 001-11889 84-0916344
--------------------------- -------------------- -----------------------
(State or other jurisdiction (Commission File No.) (IRS Employer
of incorporation) Identification No.)
8229 Boone Boulevard, Suite 802
Vienna, Virginia 22182
-------------------------------------------------
(Address of principal executive offices, including Zip Code)
Registrant's telephone number, including area code: (703) 506-9460
N/A
----------------------------
(Former name or former address if changed since last report)
Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-14(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (ss.203.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (ss.204.12b-2 of this
chapter.
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. [ ]
Item 5.02. Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On December 18, 2017 CEL-SCI Corporation appointed Robert Watson to its
Board of Directors.
Mr. Watson (age 60) has over 35 years of experience in the healthcare IT
industry as a CEO, board member and advisor to multiple companies. Having
participated in over 75 acquisitions, he has raised nearly $750,000,000 in
capital, completed three public offerings and successfully sold four companies.
Since July 2017 Mr. Watson has been the President of the Preparedness
Technology Division at EMSystems (a subsidiary of Intermedix, Inc.). Between
2015 to 2017, prior to his joining EMSystems, he was the President and Chief
Growth Officer of NantHealth, and between 2011 to 2015, he was the CEO of
Streamline Health. Both NantHealth and Streamline Health are NASDAQ listed
companies. He has held executive positions at numerous other healthcare IT
companies.
Mr. Watson holds an MBA from the Wharton School of Business at the
University of Pennsylvania and a BA from Syracuse University.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: December 20, 2017 CEL-SCI CORPORATION
By: /s/ Patricia B. Prichep
--------------------------------------
Patricia B. Prichep
Senior Vice President of Operations
